Cardiovascular and lipid mobilizing effects of tetrahydroisoquinoline.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D004285:Dogs; D004837:Epinephrine / Q000037:antagonists & inhibitors; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D006325:Heart Atria / Q000187:drug effects; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D012669:Seminal Vesicles / Q000187:drug effects*; D013565:Sympatholytics / Q000494:pharmacology*; D013566:Sympathomimetics / Q000494:pharmacology*; D014666:Vasomotor System / Q000187:drug effects*
D005230:Fatty Acids, Nonesterified; D011804:Quinolines; D013565:Sympatholytics; D013566:Sympathomimetics; D010643:Phenoxybenzamine; D001285:Atropine; D012110:Reserpine; D011433:Propranolol; D009638:Norepinephrine; D004837:Epinephrine